Litcius/Paper detail

A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition

Shengbo Sun, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang

2024Trends in cancer11 citationsDOI

Topics & Concepts

EnhancerImmunotherapyPD-L1PCSK9Cancer researchMedicineChemistryPharmacologyImmune systemInternal medicineImmunologyCholesterolBiochemistryGeneGene expressionLipoproteinLDL receptorColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition | Litcius